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Abstract
Chemotherapy is a cancer treatment modality that uses drugs to kill tumor cells.
A typical chemotherapeutic protocol consists of several drugs delivered in cycles
of three weeks. We present mathematical analyses demonstrating the existence
of a maximum time between cycles of chemotherapy for a protocol to be effec-
tive. A mathematical equation is derived, which relates such a maximum time
with the variables that govern the kinetics of the tumor and those characterizing
the chemotherapeutic treatment. Our results suggest that there are compelling
arguments supporting the use of dose-dense protocols. Finally, we discuss the
limitations of these protocols and suggest an alternative.
1. Introduction
In order to assess the benefits of the different combination chemotherapeutic
protocols, clinical experience reveals that simple trial-and-error, in the absence
of guiding principles, is a rather slow and inefficient process (Simon and Norton,
2006). To establish these guiding principles, hypotheses have to be accompa-
nied by mathematical models (Borges et al., 2014; Iarosz et al., 2015), in such
a manner that empirical data allows their rigorous falsification. Log-kill mod-
els have provided important progress in chemotherapy along the last forty years
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(Norton, 2014), specially concerning haematological cancers. However, random-
ized trials carried out in recent decades (Bonadona et al., 1995; Hudis et al., 1999;
Citron et al., 2003) have demonstrated that the periodicity of the cycles is very
important, as well. One of the reasons that support this fact is that tumors grow
between cycles of chemotherapy. Even worse, some of these proliferating cells
could be resistant to further treatment. Another reason is that there is evidence
suggesting that the rate of destruction by chemotherapy is proportional to the rate
of growth of the same tumor in the absence of therapy (Simon and Norton, 2006).
This statement is formally known as the Norton-Simon hypothesis. According
to it, and because many solid tumors follow Gompertzian or sigmoidal growth
(Laird, 1964; Norton, 1988), bigger tumors are less susceptible to therapy. All
these facts have led to the introduction of the concept of dose-dense protocols
in chemotherapy. Dose-dense chemotherapy is based on the increase in the fre-
quency of drug delivery to avoid regrowth between cycles and achieve the max-
imum cancer cell kill. It has been an important breakthrough in the evolution of
chemotherapy for breast cancer and lymphoma (Hudis and Schmitz, 2004).
However, dose-dense protocols of chemotherapy are still being debated (Foukakis et al.,
2016), and no general consensus has been reached on their beneficial proper-
ties. Moreover, as far as the authors are concerned, the role of dose-density
compared to dose-intensity has not been addressed in previous modeling efforts
(Panneta and Adam, 1995; Pinho et al., 2002; De Pillis et al., 2006) on chemother-
apy. The importance of the Norton-Simon hypothesis and how it affects the dose-
dense principle has not been rigorously established neither. This novel features
can be studied by introducing protocols of chemotherapy that are in closer re-
semblance to those used in the clinical practice. For this purpose, we devise a new
one-dimensional map for chemotherapy from a well-established continuous math-
ematical model. The discrete model is used to demonstrate the existence of a max-
imum time between cycles of chemotherapy for a treatment to be able to reduce
the tumor mass. The continuous mathematical model assumes the the sigmoidal
growth of tumors, although other types of growth can be considered to obtain
similar conclusions. Concerning chemotherapy, it is represented by means of the
Exponential Kill Model (Gardner, 1996), which was developed in the last decade,
and includes features that go beyond traditional log-kill models. We do not need
to assume the Norton-Simon hypothesis to develop our ideas. Nevertheless, we
show that such hypothesis enhances the forcefulness of our results. Before devel-
oping our ideas, it is convenient to put on a clear physical basis some concepts
commonly used in the arrangement of chemotherapeutic protocols, which might
be potentially confusing.
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2. Protocols of chemotherapy
Chemotherapy can be used in several ways (Pazdur et al., 2005). Among its
different uses, it can be administered concurrently with other treatments, such as
radiation and surgery (adjuvant chemotherapy). It can also be administered in a
long-term setting at low-doses, to a patient who has achieved a complete remis-
sion, with the intent of delaying the regrowth of residual tumor cells (maintenance
chemotherapy). Or it can be delivered to prolong life, to a patient whose cure is
not likely (palliative chemotherapy). In all these cases, chemotherapy is com-
monly delivered in periodic cycles of three weeks1, which seems to be the time
required for the organism to recuperate from the toxic side-effects of the ther-
apy (e.g. to replenish cells originated in the bone marrow). Finally, a cycle of
chemotherapy consists of several drugs, which are frequently administered intra-
venously through continuous infusion. These infusions can last from half an hour
to several hours. Therefore, four elementary variables associated to a chemother-
apeutic protocol can be distinguished. During a cycle, for each drug, there is a
variable representing the dose administered D, another that symbolizes the total
duration of the infusion ta and a third variable that represents the rate of elimina-
tion of such drug from the bloodstream k. Finally, one more variable representing
the time T between the successive cycles of the treatment is necessary.
There are two fundamental concepts related to these variables. The first is
dose-intensity, which is defined as the total dose of drug administrated during
a treatment, divided by the duration of the treatment (Fornier and Norton, 2005).
The second concept is dose-density, and it can be precisely defined as the period T
between the cycles of the treatment (Fornier and Norton, 2005). Several protocols
illustrating these two concepts are shown in Fig. 1. The confusing point is that,
since dose-intensity is defined as an average, there are two ways in which it can
be incremented. The first is to increase the dose of a drug (or the number of
drugs) given in a cycle. The second is to shorten the treatment by an increase of
dose-density (keeping fixed the total amount of drug delivered and the number of
cycles). To avoid this ambiguity, dose-intensity must be defined at every instant
of time, as the rate at which drug flows into the body I(t) = dD/dt. However, in
practice, we also define the dose-intensity as an average. In particular, we say that
the dose-intensity 〈I〉 is the average of the instantaneous dose-intensity I(t) over
1Information about standard protocols of chemotherapy has been drawn
from: http://www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols.
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Figure 1: Protocols of chemotherapy. (a) A reference protocol of chemotherapy consisting of
four cycles of the same dose of drug, given every three weeks. (b) A protocol that is more dose-
intense than the reference, because higher doses of the drug are administered (higher D). (c) A
protocol that is more dose-intense, again because more drug is administered in a cycle, but through
a longer continuous infusion (higher ta). (d) A protocol consisting of four cycles, which is more
dose-dense than the reference, because the frequency of the cycles is increased (lower T ) to one
week.
a cycle of chemotherapy. Mathematically, this can be written as
〈I〉 =
1
T
∫ T
0
I(t)dt. (1)
Now, this concept is independent of dose-density and the only way to increase it
is through an increase of dose or through the addition of more drugs to a cycle.
To conclude, we recall that other concepts, such as the cumulative dose, do not
play any role in our study, since drugs barely accumulate when the time between
cycles is considerably longer than the half-lives of the drugs. For the same reason,
the time along which drugs are administrated ta through continuous infusion, is
neglected.
3. Model description
To develop our ideas, a one-dimensional nonhomogeneous ODE model gov-
erning the dynamics of a solid tumor under the effect of cytotoxic drugs is con-
sidered. The kinetics of the tumor is assumed to be Gompertzian, although for
mathematical simplicity, the logistic equation is used. The chemotherapeutic pro-
tocol is represented by means of the Exponential Kill Model, which was designed
regarding in vitro data (Gardner, 1996) and has also been tested against in vivo
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Figure 2: The drug input. The arrows represent a protocol of four cycles of chemotherapy mod-
eled through a series of Dirac delta functions. The dashed line represents the concentration of the
drug as it is eliminated from the organism.
results (Lo´pez et al., 2014). Therefore, the mathematical equation can be written
as
dP
dt
= rP (t)
(
1−
P (t)
K
)
− b
(
1− e−ρC(t)
)
P (t), (2)
where P (t) represents the tumor cell population, r its maximum rate of growth
and K its carrying capacity. The second term represents the action of a cytotoxic
agent, being b the maximum fractional cell kill, C(t) the concentration of the drug
at the tumor site and ρ the resistance of the tumor cells to such drug.
The effect of chemotherapeutic drugs is not exerted immediately, and there ex-
ist time delays imposed by their metabolism (Lo´pez et al., 2014). However, these
delays do not alter the results of this work, since they simply displace in time the
treatment. Thus, concerning the pharmacokinetics, we simplify it as much as pos-
sible, following previous modeling efforts (De Pillis et al., 2006). This allows us
to derive analytical results. Hence, we assume a one-compartment model and first
order pharmacokinetics. The differential equation governing the concentration of
the drug is
dC
dt
= I(t)− kC(t), (3)
where I(t) is the function representing the input of drug (the instantaneous dose-
intensity) and k is the rate of elimination of the drug from the bloodstream, from
which the half-life can be computed as τ1/2 = (loge 2)/k.
If the drug is administered through an intravenous bolus or by a short contin-
uous infusion, the time along which the drug is given (from minutes to a couple
of hours) can be neglected compared to the time between cycles of chemotherapy
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(weeks), and we can safely approximate the input function as
I(t) =
Nc∑
m=0
Dδ(t−mT ), (4)
where δ(t) is the Dirac delta function and T is the time elapsed between cycles.
Therefore, every T weeks a dose of drugD is administered to the patient, during a
treatment that comprisesNc cycles of chemotherapy. Note that, with this approxi-
mation, the dose-intensity 〈I〉, as computed from equation (1), is simply given by
D. For the moment, we consider that the same dose of drug is administered with
each cycle. In Sec. 6 our results are extended to more sophisticated protocols. For
a representation of the protocol see Fig. 2. The solution to equation (3) with a
drug input given by equation (4) at a time instant t between the (n − 1)-th and
n-th cycle is
C(t) = D
enkT − 1
ekT − 1
e−kt. (5)
If the drug is eliminated quickly (in comparison to the duration of the cycle) we
can neglect the accumulation of the drug along the cycles of the treatment and use
the approximationC(t) = De−k(t−(n−1)T ), with t in the interval mentioned above.
Or more simply
C(t) = De−kt(mod T ). (6)
We now briefly describe the main features of the model dynamics. To this
end, we consider the following set of parameters, which are chosen in conformity
with experimental data. The values of r = 0.8 week−1 and K = 1 × 109 cells
have been borrowed from the literature (De Pillis et al., 2005). Since the fastest
growing tumor that can be imagined is an exponentially growing tumor with a
constant rate value of r = 4.85 week−1, we are considering a quite aggressive
tumor. The carrying capacity corresponds to a detectable tumor mass of approx-
imately one gram. The values of ρ = 0.1 mg−1 and b = 2.8 week−1 are within
values appearing in other work as well (Gardner, 1996). The dose of drug ad-
ministered in these simulations is D = 60 mg, while the rate of drug elimination
k = 4.85 week−1 corresponds to a half-life of approximately one day. These
are typical values of the drug doxorubicine, which is used in the treatment of lo-
cally advanced breast cancer, for example. Nevertheless, the effects of varying
these parameters are inspected in Sec. 5. As can be seen in Fig. 3, if the drug is
effective destroying the tumor cell population (low resistance), the tumor is con-
siderably reduced when the drug concentration is high. However, as soon as most
6
w w
Figure 3: Two protocols of chemotherapy. (a) A protocol consisting of two-week cycles
(T = 2 weeks) is able to reduce the size of the tumor (red) progressively. (b) A protocol whose
drugs are administered every four weeks (T = 4 weeks) is insufficient to reduce the size of the
tumor progressively. The time series of the drug concentration C(t) is plotted for clarity (green),
disregarding its specific values.
of the drug has been eliminated, the tumor resumes its growth. Consequently, if
the period of time between cycles is too long, the protocol leads to an oscillatory
dynamics and cannot be effective, bearing in mind that typical half-life values of
cytotoxic drugs span from several hours to several days. Unlike other cancer treat-
ments, where the drugs are given for longer periods of time and the phenomenon
of drug resistance is more pronounced (Hirata et al., 2010), in chemotherapy the
resulting oscillations are in general undesired. An example is the use of adju-
vant chemotherapy for the treatment of breast cancer, where the phenomenon of
resistance has not been demonstrated to be more important than the effect of dose-
density (Bonadona et al., 1995).
These facts suggests that, having fixed the remaining parameters of the model,
there exists a maximum time between cycles of chemotherapy that permits a pro-
gressive reduction of the tumor. And then, obviously, protocols set at values of T
higher than such threshold (i.e., not enough dose-dense), are useless. A mathe-
matical function that allows to estimate the relation between the threshold value
of the cycle periodicity and the model parameters is derived in the following sec-
tions.
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4. A one-dimensional map
To obtain a function that relates the threshold value of T with the other param-
eters of the model, we first derive a one dimensional map for cancer chemother-
apy. In dynamical systems, a map is a function that relates a set of possible
states with itself in an iterative manner. In our case, this function relates the
size of the tumor right before two successive cycles of chemotherapy. The first
assumption in this derivation is that the drugs are effective enough to reduce
the size of the tumor at some time. An upper bound for the value of r that
guarantees this condition is r < b(1 − e−ρD), which can be obtained by con-
sidering that rP (1 − P/K) ≤ rP < b
(
1− e−ρC(t)
)
P in equation (2), which
assures that P˙ < 0. Rearranging this condition we can also set a restriction
on the minimal dose of drug required for a treatment to be effective, which is
ρD > loge(b/(b − r)). For this not to hold, the particular nature of the proto-
col would not have much importance, since the only effect of chemotherapy is
just to slow the growth of the tumor, but not to reduce it. As depicted in Fig. 4,
when the drug concentration is high, the second term on the right hand side of
equation (2) dominates over the first term. Conversely, once most of the drug
has been eliminated C(t) → 0, it occurs the other way around, i.e., the second
term is vanishingly small in comparison to the first. Thus, we can divide a cycle
of chemotherapy [0, T ) into two time intervals. The first interval [0, τ) is dom-
inated by the cytotoxic drugs, and during it, equation (2) can be approximated
as
dP
dt
= −b
(
1− e−ρC(t)
)
P (t). (7)
During the second interval [τ, T ) the tumor growth prevails, and therefore we can
consider the growth term only
dP
dt
= rP (t)
(
1−
P (t)
K
)
. (8)
These two equations can be easily integrated. However, a difficulty arises in
order to estimate τ , which represents the time at which the drug concentration has
decreased to values for which the first term on the right hand side of (2) starts to
dominate over the second. One possibility is to approximate the growth of the tu-
mor to exponential. Since this value is the maximum rate at which the tumor can
grow (occurring for small tumor burdens), the value thus obtained is clearly a con-
servative overestimation. In this case, making use of equation (6), the following
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Figure 4: The action of chemotherapy. A cycle of chemotherapy of length T can be subdivided
into two time intervals. The red curve represents the time series of the tumor size P (t), while the
drug concentration C(t) is added for clarity (blue curve). During the first interval [0, τ), when the
drug concentration is high C(t) > D/N , the chemotherapeutic drugs govern the dynamics and
the tumor is reduced from its original size P (0) to a size P (τ). During the second interval [τ, T ),
which starts when the drug concentration has dropped to low levels, the tumor regrows from P (τ)
to its final size at the end of the cycle P (T ). Note that, by definition, the inequality τ ≤ T always
holds.
inequality must hold
r ≥ b
(
1− e−ρDe
−kt
)
. (9)
The value at saturation can be used to solve for τ , yielding
τ =
1
k
loge (ρD/ loge (b/(b− r))) . (10)
A simpler and less restrictive possibility is to assume that when the drug con-
centration has dropped to a certain level, its cytotoxic effect is negligible. Fol-
lowing this reasoning, we can write τ = (logeN)/k, where N represents the
fraction to which the drug concentration has dropped. Of course, comparison of
this equation with equation (10) allows to solve for N . More generally, a pru-
dent choice could be to consider that when the concentration has reduced in an
order of magnitude (N = 10), the effects of the drug can be disregarded. In fact,
for the parameter values presented in the previous section and this criterion, the
estimated values of the time τ obtained through these two different methods are
quite similar (around four days). In what follows, for simplicity, and because the
conclusions are more resounding, we consider a fixed value of N to illustrate our
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results. Nevertheless, the first approach can be used to obtain similar conclusions,
because τ grows slowly when ρD is increased.
Having explained this point, we can proceed to integrate the equations (7) and
(8). Equation (7) can be integrated as follows. In a first step we have
loge(P (τ)/P (0)) = −bτ + b
∫ τ
0
e−ρDe
−kt
dt. (11)
The integral appearing in the second term of the right hand side can be solved in
terms of the exponential integral function Ei(x) (see Appendix A). The result is∫ τ
0
e−ρDe
−kt
dt = τ
Ei(−ρD)− Ei(−ρD/N)
logeN
. (12)
If we define the fuction g as
g(ρD,N) ≡
Ei(−ρD)− Ei(−ρD/N)
logeN
, (13)
we finally obtain
P (τ) = P (0)e−bτ(1−g). (14)
The function g(x,N) is analytic in the domain of interest [0,∞) × (1,∞)
and resembles an exponential decay, as can be seen in Fig. 5. This means that
the survival fraction P (τ)/P (0) at time τ plateaus for increasing values of the
dose. The value of the survival fraction at the plateau is e−bτ . This feature is
characteristic of the Exponential Kill Model and does not appear in ordinary log-
kill models (Gardner, 1996). It states that at a certain point, which depends on the
tumor resistance to the drugs, the increase of the dose intensity barely affects the
survival fraction.
The solution to the logistic equation (8) governing the second part of the
chemotherapeutic cycle [τ, T ) is well-known. With these limits of integration,
the solution can be written as
P (T ) =
KP (τ)er(T−τ)
K + P (τ)(er(T−τ) − 1)
. (15)
To conclude, we can substitute equation (14) into equation (15) to obtain the
relation between the size of the tumor at the beginning and at the end of a cycle of
chemotherapy
P (T ) =
KP (0)
Ke−r(T−τ(1+b(1−g)/r)) + P (0)(1− e−r(T−τ))
. (16)
10
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Figure 5: The function g(x,N). The resemblance between this function and a decaying expo-
nential is shown. For x = 0 it takes a value of 1 and it has an horizontal asymptote at y = 0.
If we define the constants α = e−r(T−τ(1+b(1−g)/r)) and β = 1 − e−r(T−τ), the
sequence that relates the size of the tumor cell population right when the n-th
cycle starts and its size at the end of the cycle is
Pn+1 =
KPn
αK + βPn
. (17)
In fact, we can nondimensionalize the tumor size population by dividing it by its
carrying capacity, since it will not affect the results presented in the following
section. In the new variable x = P/K, the map is nicely written as
xn+1 = f(xn) =
xn
α + βxn
. (18)
5. The shrinking condition
We proceed to study the stability properties of the one-dimensional map de-
rived right above. The fixed points of the map satisfy the equation f(x∗) = x∗. If
chemotherapy is able to completely reduce the size of the tumor, the orbit of any
initial condition should asymptotically converge to a state of zero tumor cell pop-
ulation. In mathematical language, x∗ = 0 should be an attractor of the dynamical
system. This imposes a constraint on the values that α can take. Solving for x∗,
we find two possible solutions, which are x∗1 = 0 and x
∗
2 = (1−α)/β. To address
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the stability of the fixed points, the Jacobian has to be computed at these points.
We obtain
f ′(x∗) =
α
(α + βx∗)2
. (19)
Thus, for x∗1 = 0, the value of the Jacobian is 1/α, while for x
∗
2 = (1− α)/β, the
value is α. Since α is positive, we have two possibilities. The first one is α < 1,
where x1 is a repelling fixed point, while x2 represents a stable state in which the
tumor exists under its carrying capacity. Conversely, if α > 1, the tumor can be
eradicated, which is the desired situation. We can solve for T by expressing the
parameter α in terms of the parameters of the chemotherapeutic protocol and the
rate of growth of the tumor. The result is
T < τ(1 + b(1 − g(ρD,N))/r). (20)
As it can be seen, there certainly exists a threshold value of the period be-
tween cycles Ts = τ(1 + b(1− g(ρD,N))/r) for a chemotherapeutic protocol to
be effective. On what follows, we refer to this value as the shrinking time Ts. Pro-
tocols that are sufficiently dose-dense (i.e., T < Ts) provide a sustained reduction
of the tumor. Note that, since our estimation of the time τ does not depend on K,
there is no dependence of Ts on the carrying capacity of the tumor K. This is an
advantage, since, in general, it is not easy to determine a priori the value ofK.
We now examine the nature of the functional relation between Ts and the pa-
rameters representing the dose D, the resistance ρ, the maximum fractional cell
kill b and the rate of growth r of the tumor. Since these four parameters appear
in pairs in equation (20), ρ and D multiplying each other while b and r dividing
each other, we can simplify the study by defining two new dimensionless param-
eters from them. We call one of them the effective dose D∗ = ρD, while the
other is named the relative maximum fractional cell kill b∗ = b/r. In the fol-
lowing we consider N = 10, which, as previously stated, gives similar results
that equation (10). With the new parameters, the shrinking time can be written
as Ts = (loge 10)(1 + b
∗(1 − g(D∗, 10)))/k, where we use the same value of k
as before. As it is shown in Fig. 6, the higher the effective dose D∗, the higher
the shrinking time can be raised. However, it is clearly appreciated that the value
plateaus for high doses, and a point is reached for which increasing the dose in-
tensity does not allow to reduce noticeably the dose density. This is an important
prediction of the present work. Increasing the dose of a protocol might not be very
useful (even if there was no toxicity) if its density is under a certain value. An ap-
proximation of the limiting value is attained for D∗ → ∞ and can be computed
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Figure 6: The shrinking condition Ts. The curves Ts are represented against the effective dose
D∗ and for different values of the relative maximum fractional cell kill b∗. The colored regions
T < Ts represent sufficiently dose-dense protocols. Note how the curves asymptote to a value
T∞, showing that the increase in dose does not provide substantial benefits if the density of the
protocol is not enough.
as T∞ = τ(1 + b
∗). As shown in Fig. 6, typical values of this time span from
less than a week to several weeks. Concerning the relative fractional cell kill, it
is evident that the shrinking time increases with it. Thus, in our model, slower
growing tumors and higher maximum fractional cell kill (more destructive drugs)
permit to reduce the density of the protocol.
Even though the existence of a shrinking time does not depend on additional
hypothesis, the precise value that it takes, certainly does. It is at this point that the
Norton-Simon hypothesis comes into play. For tumors that have less proliferating
cells, the effects of chemotherapy are expected to be smaller, since chemotherapy
is more effective on proliferating than quiescent cells. This phenomenon would
maintain a similar value of b∗, by reducing the value of b. Therefore, our results
are also valid for other types of tumor growth, and are always relevant as long
as the relative maximum fractional cell kill is sufficiently small. For example,
for haematological cancers we can use exponential growth P˙ = rP instead of
equation (8) and derive equivalent equations. There is also evidence pointing to
the fact that some solid tumors do not follow a sigmoidal growth, and that their
mean radius increases linearly with time (Bru´ et al., 2003). This occurs because
only the cells on the surface of these tumors are proliferating. Again, shrinking
times can be computed following our recipe, with P˙ = rP 2/3. In principle, a
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tumor that follows this power law tends to grow considerably more slowly than
an exponentially growing tumor with the same constant rate, because of the factor
2/3 in the exponent. In the case of a single connected tumor for which only cells
on its surface grow, the constant rate is similar to the exponentially growing case.
Its value can be computed as r = (36 · piρ)1/3c, where ρ is the volumetric density
of cells and c is the rate at which the radius grows. Even if the tumor is formed by
a number N of pieces, as for example a disconnected tumor or a tumor that has
metastasized, the constant rate can be estimated as r = (36 · piρN)1/3c, which is
similar to the growth constant rates here considered. However, this does not mean
that the value b∗ is necessarily higher, because the maximum fractional cell kill of
chemotherapy b, according to the Norton-Simon hypothesis, decreases as well.
6. Combination protocols
Generally, several drugs are combined in a protocol of chemotherapy. For
example, an ordinary protocol of chemotherapy for locally advanced breast cancer
can combine at least three cytotoxic drugs, such as cyclophosphamide, epirubicin
and flurouracil (Burnell et al., 2010). It is therefore pertinent to ask if the map
obtained in Sec. 4 can be extended to derive the shrinking conditions for more
complex protocols. Fortunately, the answer is affirmative. We first consider an
imaginary protocol consisting of two drugs (see Fig. 7), which are given in an
alternate fashion (a cycle of the first drug followed by a cycle of the other drug).
Since each drug has its own parameters αi and βi, after the first cycle we have
x1 = f1(x0) =
x0
α1 + β1x0
. (21)
Then, the second cycle is applied
x2 = f2(x1) =
x1
α2 + β2x1
. (22)
Now, we have to note that equation (18) can be regarded as a Mo¨bius transfor-
mation, restricted to the real numbers and with two parameters fixed. This means
that the composition of the two maps yields the same map, but with two different
parameters (α, β). Mathematically we have f = f2 ◦ f1, with x2 = f(x0). The
new parameters are related to the old ones through the relations
α = α1α2, β = β2 + α2β1, (23)
14
which define a Lie group relation between the group elements g = (α, β) and can
be represented as the product of matrices R(g) of the form
R(g) =
(
α 0
β 1
)
. (24)
In other words, there is an underlying Lie group structure that allows us to reduce
the complex protocol to a simple one. This group representation clearly resembles
to the affine group. In fact, if α and β belonged to R>0 and R respectively, f
would define an action of the half-plane on the real line. However, in our case
α and β belong to the interval [0, 1], and therefore, the inverse element is lost
(there is no such thing as a cycle of antichemotherapy). In summary, we can
combine alternated drugs in a protocol with no difficulty to give estimations of
the shrinking time. Since we have α > 1, and α1 and α2 are exponentials, for the
present example we have
Ts =
1
2
(τ1(1 + b1(1− g(ρ1D1, N))/r) + τ2(1 + b2(1− g(ρ2D2, N))/r)). (25)
Thus, the new shrinking time is the arithmetic mean of the shrinking times of
both drugs. Finally, two or more drugs are frequently given simultaneously. The
general differential equation for a protocol with nd non-interacting drugs given
simultaneously, can be written as
dP
dt
= rP (t)
(
1−
P (t)
K
)
−
nd∑
j=0
bj
(
1− e−ρjCj(t)
)
P (t). (26)
In this case, if the drugs have very different half-lives, we can derive again the
same map, but the development is more complicated. Note that, to estimate τ
to construct the map, we have to choose between the different τj of each drug
(j = 1, ..., nd). We can consider as an approximation the maximum of these
times max τj , but this procedure complicates the integrals associated to the other
drugs, and their solution involves the gamma function. However, if the half-lives
of the drugs are not so different, we can approximate all the τj to a single value.
Then, the solution is much more simple. For example, with two drugs given
simultaneously we have the shrinking time
Ts = τ1(1 + b11(1− g(ρ11D11, N))/r + b12(1− g(ρ12D12, N))/r), (27)
where a matrix notation has been adopted for the parameters b, ρ and D, corre-
sponding to each chemotherapeutic drug. This equation tells us that giving more
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Figure 7: Protocols with several drugs. (a) An alternate protocol consisting of two drugs. (b) A
protocol consisting of two simultaneously administered drugs alternated with a single administered
drug. Note how in the latter case the time τ is approximated to the highest value of the two drugs
(red and blue).
drugs at a time allows us to relax the frequency (dose-density) of the protocol. Of
course, this comes at the expense of more toxicity.
Therefore, a general approximation of the shrinking time for an arbitrary pro-
tocol, as shown in Fig. 7, as long as the half-lives of simultaneously given drugs
are similar, is
Ts =
1
n
n∑
i=1
ni∑
j=1
τi(δij + bij(1− g(ρijDij , N))/r), (28)
where δij is the Kronecker delta and τi is the time for which simultaneously given
drugs have decayed to sufficiently low levels. The variable ni is the number of
simultaneous drugs given at the i-th step of an alternate protocol comprising n
steps. To conclude this section, we recall that if two different drugs are given
sequentially (some cycles of the first followed by a number of cycles of the sec-
ond), the whole treatment can be reduced to two subtreatments, having its own
shrinking time value each.
7. Conclusions
The existence of a shrinking time is a sound argument that supports the use
of dose-dense protocols and it is in conformity with other works on chemother-
apy (Fornier and Norton, 2005; Norton, 2005), which defend the equal impor-
tance of dose-density and dose-intensity. However, even though the administra-
tion of two-week cycles of chemotherapy represents statistically significant ad-
vantages compared to the conventional three-week administration, these benefits
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are modest (Fornier and Norton, 2005). Moreover, recent investigations demon-
strate that recurrence-free survival rates are not substantially improved by using
tailored dose-dense chemotherapy instead of standard chemotherapy over a me-
dian of five years (Foukakis et al., 2016). Among other reasons, this could be
explained by considering that, although dose-dense protocols can reduce signifi-
cantly the survival fraction at the nadir, this reduction is not enough to avoid the
regrowth of residual tumor cells. In addition, it must be recognized that, at some
point, the introduction of more dose-dense protocols presents similar difficulties
that the increase of dose-intensity. The increase of dose-density achieved by re-
ducing the cycles below one week would be a synonym of an increase in dose-
intensity. Clearly put, in the limit of small times between cycles, dose-density is
tantamount to dose escalation, which can introduce intolerable toxicities. Finally,
we recall that part of the cells that comprise a solid tumor are frequently found in
a quiescent state. In such a case too dose-dense protocols might not work, since
quiescent cells are less susceptible to chemotherapy and some time after a cycle
has caused its destruction might be necessary for these remaining cells to aban-
don their cell cycle arrest. Therefore, there is no doubt that dose-density presents
numerous difficulties.
As our study suggests, chemotherapy might sometimes present the following
contradiction. As time is given for the side-effects of chemotherapy to disappear
and for the organism to restore its homeostasis, time is also given for the tumor to
recuperate. In light of the facts argued in the previous paragraph, it is worth to ex-
amine if other treatment strategies, in addition to dose-densification, are possible.
As an example, we wonder if some kind of targeted cytostatic drugs (whenever
they exist) can be administered in a rather continuous fashion between cycles of
chemotherapy to arrest the growth of the tumor during that time. Were this pos-
sible, the targeted cytostatic drug would have the effect of arresting the growth
of the tumor only, while allowing the regrowth of healthy cells that are also de-
stroyed by the cytotoxic drugs. We acknowledge that this method presents other
difficulties, because it requires some degree of synchronization. If the cytostatic
effect of the drug persists for the time a new cycle of cytotoxic drugs starts, the
effectiveness of the last can be reduced. Again, this is so because chemotherapy
is more efficient on dividing than quiescent cells. Moreover, if we could arrest the
growth of tumor cells by means of some cytostatic targeted drug, the periodicity
of the cycles might be relaxed and the toxic effects of chemotherapeutic drugs
would be reduced. This, in turn, would perhaps allow an increase in the number
of cycles as well.
In summary, we wonder if therapies might be improved as well if non-selective
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destructive drugs are alternated with more specific and targeted drugs, which can
prevent the regrowth of the tumor cells between cycles. Taking up the old con-
cept of the magic bullet (Klaus and Ullrich, 2008) proposed by Paul Ehrlich to
denominate these selective drugs, we suggest that the cannonballs of traditional
cytotoxic chemotherapy might be complemented with the magic bullets of some
cytostatic targeted therapy administered between cycles. In principle, the idea is
fairly simple and testable. Between cycles of destruction, stasis.
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Appendix A Solution to the integral
In Sec. 4, the following result has been used
∫ τ
0
e−D
∗e−ktdt = τ
Ei(−D∗)− Ei(−D∗/N)
logeN
, (A1)
where Ei(x) is the exponential integral function, which is defined as
Ei(x) =
∫ x
−∞
et
t
dt. (A2)
Here we demonstrate the equality (A1). To this end, we first perform a change
of variables u = e−kt. Therefore, the relation between the differential elements is
du/u = −kdt. Recalling that we have considered τ = (logeN)/k, the integral in
the new variable reads
∫ τ
0
e−D
∗e−ktdt = −
τ
logeN
∫ 1/N
1
e−D
∗u
u
du. (A3)
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Now, performing another change of variables x = −D∗u, we can rewrite the
previous integral as
∫ 1/N
1
e−D
∗u
u
du =
∫
−D∗/N
−D∗
ex
x
dx. (A4)
Finally, the last integral can be expressed as the sum of two integrals in the fol-
lowing way
∫
−D∗/N
−D∗
ex
x
dx =
∫
−D∗/N
−∞
ex
x
dx−
∫
−D∗
−∞
ex
x
dx. (A5)
In this last step, the conditions D∗ > 0 and N > 1 have been used, since the
Ei(x) has a singularity at x = 0. The integrals appearing in this last equation are
precisely the Ei(x) function.
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